title: [New - direct oral anticoagulants: actual review].
abstract: In recent years the options of anticoagulant/antithrombotic therapy have extended with new - direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards "the ideal antithrombotic drug", and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.Key words: apixaban - dabigatran - DOAC - NOAC - rivaroxaban.
authors.forename: Jana
authors.initials: J
authors.lastname: Michalcová
authors.forename: Miroslav
authors.initials: M
authors.lastname: Penka
authors.forename: Alena
authors.initials: A
authors.lastname: Buliková
authors.forename: Jiřina
authors.initials: J
authors.lastname: Zavřelová
authors.forename: Andrea
authors.initials: A
authors.lastname: Štěpařová
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000931:Antidotes; D000991:Antithrombins / Q000627:therapeutic use; D000069604:Dabigatran / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D017410:Practice Guidelines as Topic; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D000069552:Rivaroxaban / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000931:Antidotes; D000991:Antithrombins; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; C000594745:idarucizumab; D000069552:Rivaroxaban; D000069604:Dabigatran